[ Price : $8.95]
FDA accepts a supplemental NDA from NeurogesX, Inc. for a 30-minute application of its Qutenza 8% for managing neuropathic pain as...[ Price : $8.95]
FDA appeals a Florida federal judges 9/12 ruling that the Federal Food, Drug, and Cosmetic Act does not give the agency the author...[ Price : $8.95]
Watson Labs files an ANDA for a generic equivalent of Novartis Exelon patch used for treating mild to moderate dementia associated...[ Price : $8.95]
FDA approves a Watson Pharmaceuticals ANDA for morphine sulfate extended-release capsules, a generic of Actavis Kadian.[ Price : $8.95]
New FDA statistics show that serious (OAI) CDER clinical trial-related inspections soared 10-fold in the past eight years and that...[ Price : $8.95]
FDA issues a complete response letter for an Alimera Sciences NDA for Iluvien for treating diabetic macular edema.[ Price : $8.95]
FDA has approved an IntelGenx NDA for CPI-300, indicated for patients with major depressive disorder.[ Price : $8.95]
FDA removes a clinical hold on Helix BioPharmas Phase 2-3 trial involving its topical interferon alpha-2b product in low-grade cer...